Targeted photothermal treatment for blood clots shows promise

Targeted photothermal treatment for blood clots shows promise
Schematic diagram of a) activated platelet-targeted IR780 immunoliposomes (Tar-IR-L & Tar-scuPA-IR-L) preparation and b) their application in an acute thrombosis mouse model for photothermal thrombolysis. Credit: Advanced Functional Materials (2022). DOI: 10.1002/adfm.202209019

Nanoparticles loaded with dye that release heat upon near-infrared irradiation could provide the key to more targeted treatment for blood clots, according to new research by the Baker Institute and Swinburne University.

Acute blockage of vessels by are the underlying cause of heart attacks and strokes and a leading cause of death and disability globally, with current drug treatments associated with major side effects including potentially fatal bleeding.

In this pre-clinical study, researchers trialed photothermal therapy, which converts to , to more safely and accurately target blood clots. This approach has already attracted attention as a new research frontier in .

The mechanism for was via clot-targeting liposomes, which are being investigated for their ability to deliver drug cargoes specifically to activated platelets, which cluster to form blood clots.

In their paper in Advanced Functional Materials, A/Prof Xiaowei Wang and colleagues also incorporated near-infrared dye within the liposome, providing the potential for faster and more potent thrombolysis under infrared-red irradiation.

Merging the bioengineering expertise of Swinburne University researchers together with the biotechnology capabilities of Baker Institute scientists, they were able to create nanoparticles that will home themselves to blood clots. The targeting mechanism of drug cargoes meant that only a low dose is required, thereby their use will prevent potential bleeding complications.

Targeted photothermal treatment for blood clots shows promise
The green image shows the platelet/clot material. The purple image shows particles that have bound to the clot. Credit: Baker Institute

They found this approach caused a significant reduction in the clot area compared to those areas treated with non-targeted liposomes, which may pave the way for a single dose treatment with fewer side effects.

They hope to build on these results to provide a viable new treatment approach to the current gold standard clot busting treatment involving plasminogen activators, which come with limitations such as poor clot penetration, the need for long infusions and subsequent risk of fatal systemic bleeding.

More information: Ahmed Refaat et al, Activated Plateletā€Targeted IR780 Immunoliposomes for Photothermal Thrombolysis, Advanced Functional Materials (2022). DOI: 10.1002/adfm.202209019

Journal information: Advanced Functional Materials

Provided by Baker Institute

Citation: Targeted photothermal treatment for blood clots shows promise (2022, December 9) retrieved 4 February 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Extending anti-clotting treatment after distal deep vein thrombosis could reduce further clot risk


Feedback to editors